Edward Uchio

Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial

Dipen J. Parekh, Isildinha M. Reis, Erik P. Castle et al. · The Lancet · 2018 · 737 citations

Urology, Surgical Oncology, Medicine +8

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 513 citations

Urology, Surgical Oncology, Genitourinary Cancer +7

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer

Daniel E. Spratt, Jingbin Zhang, María Santiago‐Jiménez et al. · Journal of Clinical Oncology · 2017 · 208 citations

Urology, Oncology, Numeric Risk +14

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Renato D. Lópes, Celestia S. Higano, Susan F. Slovin et al. · Circulation · 2021 · 141 citations · Full text